Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2014

01-06-2014 | Urologic Oncology

Prognostic Significance of CD204-Positive Macrophages in Upper Urinary Tract Cancer

Authors: Takashi Ichimura, MD, Teppei Morikawa, MD, PhD, Taketo Kawai, MD, PhD, Tohru Nakagawa, MD, PhD, Hirokazu Matsushita, MD, PhD, Kazuhiro Kakimi, MD, PhD, Haruki Kume, MD, PhD, Shumpei Ishikawa, MD, PhD, Yukio Homma, MD, PhD, Masashi Fukayama, MD, PhD

Published in: Annals of Surgical Oncology | Issue 6/2014

Login to get access

Abstract

Background

Evidence suggests that CD204-positive (CD204+) tumor-infiltrating macrophages are associated with aggressive behavior of various cancers; however, the clinical, pathological, and prognostic associations of tumor-infiltrating CD204+ macrophages in urothelial cancer have not been reported.

Methods

A tissue microarray was constructed from the centers and peripheries of 171 upper urinary tract cancers treated with nephroureterectomy. CD204 immunohistochemistry was performed. The density of CD204+ cells was calculated using image analysis software, and survival analyses were performed using the Kaplan–Meier method and multivariate Cox proportional hazards regression models.

Results

High CD204+ cell density at the centers and peripheries of tumors was significantly associated with several adverse prognostic factors, including sessile architecture, histological high-grade, presence of lymphovascular invasion, concomitant carcinoma in situ, higher tumor stage, and lymph node metastasis. High CD204+ cell density was significantly associated with shorter metastasis-free and cancer-specific survival (log-rank p < 0.001) and shorter metastasis-free survival in multivariate analysis.

Conclusions

A high density of tumor-infiltrating CD204+ macrophages was associated with aggressive behavior of upper urinary tract cancer. Our results suggest that a specific immune microenvironment may be associated with the biological behavior of urothelial cancer and that CD204 may serve as a novel prognostic biomarker for these tumors.
Appendix
Available only for authorised users
Literature
1.
Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer. 2007;7(2):139–147.PubMedCrossRef
2.
Wang T, Niki T, Goto A, et al. Hypoxia increases the motility of lung adenocarcinoma cell line A549 via activation of the epidermal growth factor receptor pathway. Cancer Sci. 2007;98(4):506–511.PubMedCrossRef
3.
Matsubara D, Morikawa T, Goto A, Nakajima J, Fukayama M, Niki T. Subepithelial myofibroblast in lung adenocarcinoma: a histological indicator of excellent prognosis. Mod Pathol. 2009;22(6):776–785.PubMed
4.
Lu T, Gabrilovich DI. Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment. Clin Cancer Res. 2012;18(18):4877–4882.PubMedCentralPubMedCrossRef
5.
Rahir G, Moser M. Tumor microenvironment and lymphocyte infiltration. Cancer Immunol Immunother. 2012;61(6):751–759.PubMedCrossRef
6.
Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500–504.PubMedCentralPubMedCrossRef
7.
Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66(2):605–612.PubMedCrossRef
8.
Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4(1):71–78.PubMedCrossRef
9.
Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008;216(1):15–24.PubMedCrossRef
10.
Ohtaki Y, Ishii G, Nagai K, et al. Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J Thorac Oncol. 2010;5(10):1507–1515.PubMedCrossRef
11.
Kurahara H, Shinchi H, Mataki Y, et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res. 2011;167(2):e211–219.PubMedCrossRef
12.
Hirayama S, Ishii G, Nagai K, et al. Prognostic impact of CD204-positive macrophages in lung squamous cell carcinoma: possible contribution of Cd204-positive macrophages to the tumor-promoting microenvironment. J Thorac Oncol. 2012;7(12):1790–1797.PubMedCrossRef
13.
Ito M, Ishii G, Nagai K, Maeda R, Nakano Y, Ochiai A. Prognostic impact of cancer-associated stromal cells in patients with stage I lung adenocarcinoma. Chest. 2012;142(1):151–158.PubMedCrossRef
14.
Yoshikawa K, Mitsunaga S, Kinoshita T, et al. Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head. Cancer Sci. 2012;103(11):2012–2020.PubMedCrossRef
15.
Ino Y, Yamazaki-Itoh R, Shimada K, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013;108(4):914–923.PubMedCentralPubMedCrossRef
16.
Shigeoka M, Urakawa N, Nakamura T, et al. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Cancer Sci. 2013;104(8):1112–1119.PubMedCrossRef
17.
Grignon DJ. The current classification of urothelial neoplasms. Mod Pathol. 2009;22 Suppl 2:S60–69.PubMedCrossRef
18.
Roupret M, Babjuk M, Comperat E, et al. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol. 2013;63(6):1059–1071.PubMed
19.
Morikawa T, Hino R, Uozaki H, et al. Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro. Hum Pathol. 2010;41(12):1742–1748.PubMedCrossRef
20.
Morikawa T, Sugiyama A, Kume H, et al. Identification of toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clin Cancer Res. 2007;13(19):5703–5709.PubMedCrossRef
21.
Braun M, Kirsten R, Rupp NJ, et al. Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system. Histol Histopathol. 2013;28(5):605–610.PubMed
22.
Miyata Y, Watanabe S, Kanetake H, Sakai H. Thrombospondin-1-derived 4N1 K peptide expression is negatively associated with malignant aggressiveness and prognosis in urothelial carcinoma of the upper urinary tract. BMC Cancer. 2012;12:372.PubMedCentralPubMedCrossRef
23.
Takeda T, Kikuchi E, Mikami S, et al. Prognostic role of KiSS-1 and possibility of therapeutic modality of metastin, the final peptide of the KiSS-1 gene, in urothelial carcinoma. Mol Cancer Ther. 2012;11(4):853–863.PubMedCrossRef
24.
Liang PI, Li WM, Wang YH, et al. HuR cytoplasmic expression is associated with increased cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma. BMC Cancer. 2012;12:611.PubMedCentralPubMedCrossRef
25.
Miyazaki Y, Kosaka T, Mikami S, et al. The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma. Clin Cancer Res. 2012;18(15):4145–4153.PubMedCrossRef
26.
Yoshimine S, Kikuchi E, Kosaka T, et al. Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma. Br J Cancer. 2013;108(11):2312–2320.PubMedCrossRef
27.
Pignot G, Colin P, Zerbib M, et al. Influence of previous or synchronous bladder cancer on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelialcarcinoma. Urol Oncol. 2014;32(1):23.e1-8.CrossRef
28.
Kitamura H, Torigoe T, Hirohashi Y, et al. Prognostic impact of the expression of ALDH1 and SOX2 in urothelial cancer of the upper urinary tract. Mod Pathol. 2013;26(1):117–124.PubMedCrossRef
29.
Chromecki TF, Bensalah K, Remzi M, et al. Prognostic factors for upper urinary tract urothelial carcinoma. Nat Rev Urol. 2011;8(8):440–447.PubMedCrossRef
30.
Lughezzani G, Burger M, Margulis V, et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol. 2012;62(1):100–114.PubMed
31.
Komohara Y, Hasita H, Ohnishi K, et al. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci. 2011;102(7):1424–1431.PubMedCrossRef
32.
Komohara Y, Horlad H, Ohnishi K, et al. M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma. J Clin Exp Hematop. 2011;51(2):93–99.PubMedCrossRef
33.
Nonomura N, Takayama H, Kawashima A, et al. Decreased infiltration of macrophage scavenger receptor-positive cells in initial negative biopsy specimens is correlated with positive repeat biopsies of the prostate. Cancer Sci. 2010;101(6):1570–1573.PubMedCrossRef
34.
Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology: analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011;8(12):711–719.PubMedCentralPubMedCrossRef
35.
36.
Hagemann T, Wilson J, Burke F, et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol. 2006;176(8):5023–5032.PubMedCrossRef
37.
Wyckoff J, Wang W, Lin EY, et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004;64(19):7022–7029.PubMedCrossRef
38.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444.PubMedCrossRef
39.
Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51.PubMedCrossRef
40.
Neyen C, Pluddemann A, Mukhopadhyay S, et al. Macrophage scavenger receptor a promotes tumor progression in murine models of ovarian and pancreatic cancer. J Immunol. 2013;190(7):3798–3805.PubMedCentralPubMedCrossRef
41.
Gao Q, Zhou J, Wang XY, et al. Infiltrating memory/senescent T cell ratio predicts extrahepatic metastasis of hepatocellular carcinoma. Ann Surg Oncol. 2012;19(2):455–466.PubMedCrossRef
42.
Tsuchikawa T, Md MM, Yamamura Y, Shichinohe T, Hirano S, Kondo S. The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma. Ann Surg Oncol. 2012;19(5):1713–1719.PubMedCrossRef
43.
Katz SC, Bamboat ZM, Maker AV, et al. Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol. 2013;20(3):946–955.PubMedCentralPubMedCrossRef
44.
Lee WS, Kang M, Baek JH, Lee JI, Ha SY. Clinical impact of tumor-infiltrating lymphocytes for survival in curatively resected stage IV colon cancer with isolated liver or lung metastasis. Ann Surg Oncol. 2013;20(2):697–702.PubMedCrossRef
45.
Yopp AC, Shia J, Butte JM, et al. CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2012;19 Suppl 3:S339–346.PubMedCrossRef
46.
Gu FM, Gao Q, Shi GM, et al. Intratumoral IL-17(+) cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2012;19(8):2506–2514.PubMedCrossRef
Metadata
Title
Prognostic Significance of CD204-Positive Macrophages in Upper Urinary Tract Cancer
Authors
Takashi Ichimura, MD
Teppei Morikawa, MD, PhD
Taketo Kawai, MD, PhD
Tohru Nakagawa, MD, PhD
Hirokazu Matsushita, MD, PhD
Kazuhiro Kakimi, MD, PhD
Haruki Kume, MD, PhD
Shumpei Ishikawa, MD, PhD
Yukio Homma, MD, PhD
Masashi Fukayama, MD, PhD
Publication date
01-06-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 6/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3503-2

Other articles of this Issue 6/2014

Annals of Surgical Oncology 6/2014 Go to the issue

Reconstructive Oncology

Outcome Analysis of Expander/Implant Versus Microsurgical Abdominal Flap Breast Reconstruction: A Critical Study of 254 Cases

Thoracic Oncology

Pemetrexed-Carboplatin Adjuvant Chemotherapy With or Without Gefitinib in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Harbouring EGFR Mutations: A Randomized, Phase II Study

Breast Oncology

Basal Subtype, as Approximated by Triple-Negative Phenotype, is Associated with Locoregional Recurrence in a Case–Control Study of Women with 0–3 Positive Lymph Nodes After Mastectomy

Colorectal Cancer

MRI and FDG-PET for Assessment of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer

Translational Research and Biomarkers

Molecular Imaging of Tumor-Associated Angiogenesis Using a Novel Magnetic Resonance Imaging Contrast Agent Targeting αvβ3 Integrin

Gastrointestinal Oncology

Follow-Up After Gastrectomy for Cancer: An Appraisal of the Italian Research Group for Gastric Cancer